Spyre Therapeutics, Inc. (SYRE)
47.59
+1.91
(+4.18%)
USD |
NASDAQ |
Mar 26, 11:00
Spyre Therapeutics Cash from Investing (Quarterly) : -247.41M for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Tyra Biosciences, Inc. | 34.38M |
| Savara, Inc. | -93.56M |
| Agios Pharmaceuticals, Inc. | 90.08M |
| Tandem Diabetes Care, Inc. | -14.98M |
| ACADIA Pharmaceuticals, Inc. | -55.87M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -44.65M |
| Cash from Financing (Quarterly) | 312.88M |
| Free Cash Flow | -169.41M |
| Free Cash Flow Per Share (Quarterly) | -0.5946 |
| Free Cash Flow to Equity (Quarterly) | -44.65M |
| Free Cash Flow to Firm (Quarterly) | -44.65M |
| Free Cash Flow Yield | -5.54% |